A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects
Latest Information Update: 21 Mar 2022
Price :
$35 *
At a glance
- Drugs Sutezolid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 14 Mar 2022 Results published in the Antimicrobial Agents and Chemotherapy
- 06 Feb 2018 Status changed from recruiting to completed.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.